Healthcare | June 16, 2022
EPR-Technologies announces new approach to emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Amarex Clinical Research guides its client to phase II of FDA trials
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Subscribe To Our Newsletter & Stay Updated
